Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor

Launched by INSTITUT CANCEROLOGIE DE L'OUEST · Aug 30, 2018

Keywords

ClinConnect Summary

Anemia is a common clinical situation in oncology. It contributes to the asthenia and thus to the decrease in the quality of life of the patient. In addition, it is considered an independent pejorative prognostic factor according to a literature review of 2001. An appropriate management of the latter is therefore paramount. To do this, it is necessary to successfully define its origins.

In 2014, RET-he was studied for the first time in the cancer patient. This analysis showed that there is a good negative predictive value of RET-he for a cut-off of 32 PG, i.e., that above this value the ir...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • Metastatic solid tumor or not.
• * Anemia by functional martial deficiency (as defined in the NCCN2016 recommendations):
• • o Hb \< 11 g/DL, TSAT \< 20% and ferritinlike between 30 and 800 ng/ml
• • Initial assessment of anemia carried out at the laboratory of Biopathology of the ICO
• Exclusion Criteria:
• • Patient with malignant hemopathy.
• • Patient with chronic renal failure with an estimation of renal filtration rate according to the formula CKD-EPI \< 60 ml/min/1.73 m².
• • Patient with vitamin B12 deficiency, folate deficiency, hemolysis and/or hemoglobinopathy.
• • Patient with active infection.
• • Patient with bone marrow tumor. Confirmation by a osteo-medullary biopsy (BOM) or a myelogram is not necessary to exclude the patient.
• • Patient who received ASE within two months prior to the initial blood test.
• • Patient who received iron (oral or injectable) in the two months preceding the initial blood test.
• • Patient who received a transfusion of globular pellets in the month preceding the initial blood test.